We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 2, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include ExxonMobil (XOM - Free Report) , Disney (DIS - Free Report) , AbbVie (ABBV - Free Report) , Bristol-Myers (BMY - Free Report) and United Continental (UAL - Free Report) .
Top Analyst Reports for ExxonMobil, Disney & AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil, Disney and AbbVie. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-ranked ExxonMobil’s shares have gained +16.1% over the past six months, outperforming the Zacks Integrated Oil industry, which gained +12.4% over the same period. The Zacks analyst thinks the company has a leading position in the energy industry owing to its size and diverse asset base, both in terms of business mix and geographical footprint.
With a stable cash position, the company’s balance sheet is one of the best in the industry. This has allowed ExxonMobil to reward stockholders with a 6.3% average annual dividend hike over the past 35 years. The company owns some of the most prolific upstream assets globally along with the largest global refining operations.
Notably, ExxonMobil continues to gain on ramped-up oil-equivalent production from Hebron field. Moreover, to address the transport constraints and pump out five times more oil from the Permian through 2025, ExxonMobil is investing billions in the basin’s midstream infrastructure.
Shares of Disney have increased +8.8% year to date, outperforming the Zacks Media Conglomerates industry’s +8.5% gain in that same time period. The Zacks analyst thinks Disney’s top-line will benefit from the solid line-up of big-budget movies slated to be released over the next 18 months.
Parks & Resorts segment continues to show robust performances both domestically and internationally owing to a rise in customer spending, higher ticket prices and attendance. ESPN+, the company’s sports streaming service, achieved the 1 million subscriber base milestone, which is positive for Disney’s upcoming direct-to-consumer service.
However, Disney’s ongoing investments on its technology platform are expected to keep margins under pressure. Additionally, higher programming costs at ESPN remains a concern. Moreover, weakness in the Consumer Products & Interactive Media segment is a headwind.
Buy-ranked AbbVie’s shares have lost -2.2% year to date, underperforming the Zacks Large Cap Pharmaceuticals industry's rally of +7.1%. The Zacks analyst thinks AbbVie’s key drug, Humira has been performing well based on strong demand trends, despite new competition.
Moreover, Imbruvica has multibillion-dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Mavyret’s launch has also been stronger than expected. Mavyret has become a major growth driver for AbbVie in a short time on the market.
AbbVie has an impressive late-stage pipeline with the launch of several products with multibillion-dollar potential expected in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. However, potential biosimilar competition to Humira in Europe this year is an overhang.
Other noteworthy reports we are featuring today include Bristol-Myers and United Continental.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental
For Immediate Release
Chicago, IL – October 2, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include ExxonMobil (XOM - Free Report) , Disney (DIS - Free Report) , AbbVie (ABBV - Free Report) , Bristol-Myers (BMY - Free Report) and United Continental (UAL - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for ExxonMobil, Disney & AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil, Disney and AbbVie. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Buy-ranked ExxonMobil’s shares have gained +16.1% over the past six months, outperforming the Zacks Integrated Oil industry, which gained +12.4% over the same period. The Zacks analyst thinks the company has a leading position in the energy industry owing to its size and diverse asset base, both in terms of business mix and geographical footprint.
With a stable cash position, the company’s balance sheet is one of the best in the industry. This has allowed ExxonMobil to reward stockholders with a 6.3% average annual dividend hike over the past 35 years. The company owns some of the most prolific upstream assets globally along with the largest global refining operations.
Notably, ExxonMobil continues to gain on ramped-up oil-equivalent production from Hebron field. Moreover, to address the transport constraints and pump out five times more oil from the Permian through 2025, ExxonMobil is investing billions in the basin’s midstream infrastructure.
(You can read the full research report on ExxonMobil here >>>).
Shares of Disney have increased +8.8% year to date, outperforming the Zacks Media Conglomerates industry’s +8.5% gain in that same time period. The Zacks analyst thinks Disney’s top-line will benefit from the solid line-up of big-budget movies slated to be released over the next 18 months.
Parks & Resorts segment continues to show robust performances both domestically and internationally owing to a rise in customer spending, higher ticket prices and attendance. ESPN+, the company’s sports streaming service, achieved the 1 million subscriber base milestone, which is positive for Disney’s upcoming direct-to-consumer service.
However, Disney’s ongoing investments on its technology platform are expected to keep margins under pressure. Additionally, higher programming costs at ESPN remains a concern. Moreover, weakness in the Consumer Products & Interactive Media segment is a headwind.
(You can read the full research report on Disney here >>>).
Buy-ranked AbbVie’s shares have lost -2.2% year to date, underperforming the Zacks Large Cap Pharmaceuticals industry's rally of +7.1%. The Zacks analyst thinks AbbVie’s key drug, Humira has been performing well based on strong demand trends, despite new competition.
Moreover, Imbruvica has multibillion-dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Mavyret’s launch has also been stronger than expected. Mavyret has become a major growth driver for AbbVie in a short time on the market.
AbbVie has an impressive late-stage pipeline with the launch of several products with multibillion-dollar potential expected in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. However, potential biosimilar competition to Humira in Europe this year is an overhang.
(You can read the full research report on AbbVie here >>>).
Other noteworthy reports we are featuring today include Bristol-Myers and United Continental.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.